Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough R&D Pipeline Sticks To Traditional Strengths

Executive Summary

Schering-Plough's R&D efforts build on the company's existing therapeutic areas, according to the drug maker's R&D update Nov. 1

You may also be interested in...



Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.

Pfizer should conduct wide-ranging postmarketing studies to gather additional safety information on its CCR5 co-receptor antagonist maraviroc, FDA's Antiviral Drugs Advisory Committee recommended

Pfizer Should Expand Maraviroc Postmarketing Safety Plans – Cmte.

Pfizer should conduct wide-ranging postmarketing studies to gather additional safety information on its CCR5 co-receptor antagonist maraviroc, FDA's Antiviral Drugs Advisory Committee recommended

Schering-Plough To Hone Its Edge In “Build The Base” Phase

Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel